GSK settles a nasal lawsuit

City A.M. Reporter
DRUGMAKER GlaxoSmithKline has reached a $150m preliminary settlement with US drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, court documents show.

The settlement was reached with, among others, AmerisourceBergen , Cardinal Health and McKesson, who maintained that Glaxo had abused the citizen’s petition process to maintain a market monopoly.